Patents Examined by Xiaozhen Xie
  • Patent number: 11655283
    Abstract: Embodiments of the disclosure pertain to the field of HLA-G molecules and their therapeutic use. The disclosure pertains to new HLA-G isoforms, that is to say new RNA transcripts and proteins deriving from the HLA-G gene, pharmaceutical composition comprising thereof, as well as primers specific of these transcripts and antibodies specific of these proteins. The disclosure further pertains to the diagnostic or therapeutic use of these molecules.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: May 23, 2023
    Inventors: Edgardo D. Carosella, Diana Tronik-Le Roux, Jean-Philippe Deslys, Jérôme Verine, François Desgrandchamps, Nathalie Rouas-Freiss, Joël Le Maoult
  • Patent number: 11656227
    Abstract: Provided herein are biomarkers and methods for generating scores useful for assessing psoriatic arthritis (PsA) disease activity in subjects previously diagnosed with PsA. The invention also provides predictive model methods based on the biomarkers, as well as computer systems, software embodiments of the models for scoring and optionally classifying samples, and methods of recommending optimal therapeutic regimens.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: May 23, 2023
    Inventors: Eric Sasso, Paul Scott Eastman, Rebecca Bolce, Arthur Kavanaugh
  • Patent number: 11648290
    Abstract: Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or binds to the cartilage of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of a drug to a target region, tissue, structure or cell in the cartilage. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures or cells targeted by the peptide.
    Type: Grant
    Filed: June 21, 2021
    Date of Patent: May 16, 2023
    Inventors: James Olson, Andrew David Strand, Emily June Girard, Roland Strong, Christopher Mehlin, Colin Correnti, Natalie Nairn
  • Patent number: 11624060
    Abstract: The invention generally relates to collagen-binding agent compositions and methods of using the same. More specifically, the invention relates in part to new collagen-binding agent compositions and methods that may be used to treat damaged collagen within tissues or used to specifically target therapeutics to tissues containing undamaged or damaged collagen.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: April 11, 2023
    Assignees: The Board of Trustees of the University of Arkansas, The Kitasato Institute
    Inventors: Joshua Sakon, Jeffrey Roeser, Ryan Bauer, Katarzyna Janowska, Keisuke Tanaka, Osamu Matsushita, Kentaro Uchida
  • Patent number: 11612620
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating rheumatoid arthritis, and a stem cell therapeutic agent for treating rheumatoid arthritis, comprising nasal inferior turbinate-derived mesenchymal stem cells as an active ingredient. Nasal inferior turbinate-derived mesenchymal stem cells of the present invention have the effects of reducing the production of interleukin-17A (IL-17A), tumor necrosis factor-? (TNF-?), immunoglobulin G2 (IgG2a) which is an inflammation-inducing factor, and/or the proliferative ability of lymph node T cells, increasing interleukin-10 (IL-10) and/or regulatory T-cells (Treg, CD4+CD25+foxp3+ cell) that contribute to immune tolerance in spleen cells, and inhibiting the proliferation of human T-cells.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: March 28, 2023
    Inventors: Sung Won Kim, Seung Ki Kwok, Jaeseon Lee, Sun hwa Park, Jung Yeon Lim
  • Patent number: 11608374
    Abstract: The present invention provides anti-sclerostin antibodies and methods of using the same. In some embodiments, an isolated anti-sclerostin antibody of the present invention is a multispecific antibody. The present invention also provides isolated nucleic acids encoding an anti-sclerostin antibody of the present invention. The present invention also provides host cells comprising a nucleic acid of the present invention. The present invention also provides a method of producing an antibody comprising culturing a host cell of the present invention so that the antibody is produced. The present invention also provides a pharmaceutical formulation comprising an anti-sclerostin antibody of the present invention and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: March 21, 2023
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventor: Zenjiro Sampei
  • Patent number: 11603408
    Abstract: The present invention provides methods for treating, preventing or ameliorating skin infections, including bacterial and viral infections. In certain embodiments, the invention provides methods to reduce skin infection in a patient with atopic dermatitis (AD). Also provided are methods for improving skin barrier function, and methods for reducing the risk of inflammation due to microbial infection in a patient in need thereof. The methods of the present invention comprise administering to a patient in need thereof a pharmaceutical composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody.
    Type: Grant
    Filed: May 28, 2019
    Date of Patent: March 14, 2023
    Assignees: Regeneron Pharmaceuticals, Inc., Sanofi Biotechnology
    Inventors: Neil Graham, Marius Ardeleanu, Allen Radin, Jennifer D. Hamilton, Ariel Teper
  • Patent number: 11591403
    Abstract: Provided by the disclosure are compositions and methods for modulating differentiation of regulatory T cells. In some embodiments, methods include selectively decreasing IL-23R activity and/or IL-23R expression without significantly decreasing IL-12RP activity and/or IL-12RP expression.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: February 28, 2023
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Harvey Cantor, Hye-Jung Kim, Jessica M. Sido
  • Patent number: 11571497
    Abstract: A method for promoting growth of bone, periodontium, ligament, or cartilage in a mammal by applying to the bone, periodontium, ligament, or cartilage a composition comprising platelet-derived growth factor at a concentration in the range of about 0.1 mg/mL to about 1.0 mg/mL in a pharmaceutically acceptable liquid carrier and a pharmaceutically-acceptable solid carrier.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: February 7, 2023
    Assignee: BioMimetic Therapeutics, LLC
    Inventor: Samuel E. Lynch
  • Patent number: 11560413
    Abstract: The present invention is directed to modified CFTR proteins or fragments thereof that contain single or multiple amino acid mutations to improve the structural stability of such CFTR proteins and/or fragments. Specifically, the modified CFTR proteins or fragment thereof differ from the wild-type human CFTR protein or fragment thereof by the presence of four or more mutations selected from V150D, M470V, S492P, F494N, S495P, A534P, I539T, G550E, G551D, R553Q, R555K, Q637R, S1255L, K1334G, S1359A, E1371Q, H1402S, Q1411D, and any combination thereof, such that the stability of the polypeptide is increased relative to that of the wild-type human CFTR polypeptide or fragment thereof.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: January 24, 2023
    Assignees: UAB Research Foundation, Texas Tech University System
    Inventors: John C. Kappes, Zhengrong Yang, Christie G. Brouillette, Ina L. Urbatsch
  • Patent number: 11559567
    Abstract: A pegylated type I interferon for use in treating an infectious disease, cancer, or myeloproliferative disease in a subject in need thereof, wherein a 50 to 540 ?g dose of the pegylated type I interferon is administered to the subject at a regular interval for a treatment period, the interval being 3 to 8 weeks.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: January 24, 2023
    Assignee: PharmaEssentia Corporation
    Inventors: Christoph Klade, Oleh Zagrijtschuk, Ko-Chung Lin
  • Patent number: 11560594
    Abstract: Provided herein are methods and biomarkers useful for detecting and diagnosing osteoarthritis and predicting the progression of osteoarthritis in subjects. The diagnoses and predictions of prognosis may be used to develop treatment plans for subjects. Also included are methods of treating subjects and administering pharmaceuticals based on the diagnosis and prognosis predictions.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: January 24, 2023
    Assignee: Duke University
    Inventors: Virginia B. Kraus, Jonathan B. Catterall, Erik Soderblom, Martin A. Moseley, Sunil Suchindran
  • Patent number: 11547780
    Abstract: An inducer is directed to the induction of in situ regeneration in regenerative medicine. The inducer including an extracellular matrix and/or a bone morphogenetic protein, can induce the regeneration of bone and soft tissues surrounding the bone such as muscle, blood vessel and skin at the residual tissues where trauma occurs. The amount of regenerated tissue is associated with the dose of the implanted inducer.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: January 10, 2023
    Inventor: Yingqin Liu
  • Patent number: 11542326
    Abstract: The present invention provides antibodies that bind to human interleukin-25 (IL-25) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human IL-25 with high affinity. In certain embodiments, the invention includes antibodies that bind human IL-25 and block IL-25-mediated cell signaling. The antibodies of the invention may be fully human, non-naturally occurring antibodies. The antibodies of the invention are useful for the treatment of various disorders associated with IL-25 activity or expression, including asthma, allergy, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, atopic dermatitis (AD), and Eosinophilic Granulomatosis with Polyangiitis (EGPA), also know as Churg-Strauss Syndrome.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: January 3, 2023
    Inventors: Jamie M. Orengo, Jeanne Allinne
  • Patent number: 11524997
    Abstract: The present invention relates to methods for the treatment of a bone fracture or bone defect. The invention discloses the effective use of an anti-gremlin-1 antibody to accelerate the healing and bridging of bone tissue in segmental gap defects; and demonstrates that inhibitors of gremlin-1 activity may provide improved therapies for treating or preventing fracture non-union.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: December 13, 2022
    Inventors: Gareth Charles Glyndwr Davies, Scott John Roberts
  • Patent number: 11518802
    Abstract: The invention relates to monoclonal antibodies, in particular against a peptide of the BAMBI protein, as well as the uses thereof and methods comprising same. Preferably, the antibodies are used for the treatment of autoimmune diseases.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: December 6, 2022
    Inventors: Jesús Merino Pérez, Ramón Merino Pérez
  • Patent number: 11491180
    Abstract: There is disclosed herein compositions, methods, uses and systems for reducing pain in a patient that emanates from a body area, preferably spine or joint. Methods of treatment or prevention are described for a disease or condition selected from degenerative disc disease, disc injury, pain, arthritis, or suspected arthritis.
    Type: Grant
    Filed: June 25, 2021
    Date of Patent: November 8, 2022
    Inventors: William Mark Erwin, Bjorn C. J. Eek
  • Patent number: 11492397
    Abstract: Disclosed are compositions and methods related to IL-25 binding molecules.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: November 8, 2022
    Inventors: Richard A. Shimkets, Crystal Lyles Jackson, Nathan Bartlett, Thomas Vincent, Yonghua Luo
  • Patent number: 11484573
    Abstract: The invention features polypeptides that include an extracellular ActRlla variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRlla variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving bone damage, e.g., primary osteoporosis, secondary osteoporosis, osteopenia, osteopetrosis, fracture, bone cancer or cancer metastasis-related bone loss, Paget's disease, renal osteodystrophy, treatment-related bone loss, diet-related bone loss, bone loss associated with the treatment of obesity, low gravity-related bone loss, or immobility-related bone loss.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: November 1, 2022
    Assignee: Keros Therapeutics, Inc.
    Inventors: Jennifer Lachey, Jasbir S. Seehra
  • Patent number: 11478532
    Abstract: The present invention discloses a novel therapeutic intervention for osteoporosis. The present invention discloses that Interleukin-3 (IL-3) can be utilized as a therapeutic intervention against osteoporosis and for regulating bone homeostasis. The present invention also provides a method for determining the pre-disposition of a subject for osteoporosis by measuring the RANKL/OPG level.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: October 25, 2022
    Inventors: Kanupriya Singh, Mohan Ramchandra Wani